Basic Information
| LncRNA/CircRNA Name | SNHG3 |
| Synonyms | NA |
| Region | GRCh38_1:28505980-28510892 |
| Ensemble | ENSG00000242125 |
| Refseq | NR_002909.1 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | sorafenib | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | hepatocellular carcinoma |
| ICD-0-3 | C22.0 |
| Methods | qPCR, Western blot |
| Sample | hepatocellular carcinoma tissues, cell lines (PLC/PRF/5, Hep3B, HepG2, MHCC97L, Huh7, SMMC-7721, HCCLM3) |
| Expression Pattern | up-regulated |
| Function Description | SNHG3 expression was significantly higher in the highly metastatic HCC (HCCLM3) cells compared with the lowly metastatic HCC cells. forced expression of SNHG3 promoted cell invasion, epithelial-mesenchymal transition (EMT), and sorafenib resistance in HCC. SNHG3 overexpression induced HCC cells EMT via miR-128/CD151 cascade activation. Clinically, our data revealed that increased SNHG3 expression is correlated with poor HCC survival outcomes and sorafenib response. |
| Pubmed ID | 30132868 |
| Year | 2018 |
| Title | LncRNA SNHG3 induces EMT and sorafenib resistance by modulating the miR-128/CD151 pathway in hepatocellular carcinoma. |
External Links
| Links for SNHG3 | GenBank HGNC NONCODE |
| Links for hepatocellular carcinoma | OMIM COSMIC |